Strides receives USFDA approval for Sevelamer Carbonate Tablets
Sevelamer Carbonate Tablets approval consolidates the company's position in the Sevelamer segment
Sevelamer Carbonate Tablets approval consolidates the company's position in the Sevelamer segment
The product is used to treat amyotrophic lateral sclerosis
Travoprost Ophthalmic Solution USP, 0.004%, is indicated for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension.
Colchicine Capsules are indicated for prophylaxis of gout flares in adult
The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD) Prozac Tablets of Eli Lilly
The approved product has an estimated market size of US$ 44.5 million for the twelve months ending January 2024
The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD) Neurontin Tablets, 600 mg and 800 mg, of Viatris Specialty
The product will be launched in March 2024
It is indicated for the inhibition of premature luteinizing hormone (LH) surges in women undergoing controlled ovarian hyperstimulation
Subscribe To Our Newsletter & Stay Updated